Bioactive wound care is defined as a class of wound dressings that provide biodegradable properties and are capable of preventing microbial infection. These type of dressing control the infection and helps in faster healing. Traditionally wound dressing used to protect the wound site from contamination only, but nowadays solid wound dressing is widely used in wound healing as they provide better prolonged residence at the wound site and exudate management. Such advanced dressing has biological activity either on its own or the release of bioactive compounds incorporated with dressings. The compounds in bioactive wound dressings include alginates, hydrocolloids, collagen, and chitin, among others.
The global bioactive wound care market size is expected to reach close to 8.82 billion by 2029 with an annualized growth rate of 6.90 % through the projected period.
Rising incidence of diabetes coupled with growing aging population mainly suffer from health associated challenges such as wound healing owing to high blood sugar level in body. As a resultant requirement of effective and economic dressing is likely to play significant role in demand for bioactive wound dressing.
Increasing number of acute and chronic wounds patients, is likely to boost the global bioactive wound care market
Rising number of acute and chronic wounds such as diabetic foot ulcers, arterial ulcers and pressure ulcers that require special wound treatment and high demand for medicated wound dressing products are the factors contributing to the growth of global bioactive wound care market. In addition, increasing surgical procedures for chronic conditions such as cancer is also boosting the growth of the global bioactive wound care market. According to World Healthcare Organization (WHO), globally the number of new cancer cases increased by 18.1 million in 2018. As a result, requirement of bioactive wound care dressing is likely to play significant role in growth of the market. However, high cost of bioactive wound care products and greater availability of substitutes is likely to hamper the growth of global the bioactive wound care market.
Moist wound care is expected to dominate the market across the world
Among the considered product types, moist wound care is expected to dominate the market as it promotes faster healing as compared to others. In this procedure, wound is kept in a moist environment to heal, and thus deliver quicker results. In addition, it decreases the incidence of wound infection as well as preserves growth factors in wound fluid and stimulates collagen synthesis, which works as the base of tissue that helps in wound healing. These factors contribute to the rising demand for moist wound care, and therefore of bioactive wound care products.
North America is expected to have largest share in the global bioactive wound care market
Geographically, the global bioactive wound care market is classified into North America, Europe, Asia Pacific, Central & South America and Middle East & Africa. However, North America is expected to be the market leader through the forecast period owing to existence of large diabetic patient pool and swift adoption of advanced wound care technologies. As per the Centers for Disease Control and Prevention, more than 100 million adults in the U.S. are suffering from diabetes which further led to diabetic wound care treatment. Hence, this factor contributes to the growth of the global bioactive wound care market.
Key Market Players
- Smith & Nephew PLC
- 3M Healthcare Ltd.
- ConvaTec Inc.
- Molnlycke Healthcare AB
- Smith & Nephew PLC
- Organogenesis Inc.
- BSN Medical Inc.
- Medtronic PLC
- Paul Hartmann AG
- Covalon Technologies Ltd.
bioactive wound care market Scope
|Forecast Unit||Value (USD)|
|Revenue forecast in 2029||USD 8.82 billion|
|Growth Rate||CAGR of 6.90 % during 2019-2029|
|Segment Covered||By Product, Wound Type, End user, Regions|
|Regions Covered||North America, Europe, Asia Pacific, South America, Middle East and Africa|
|Key Players Profiled||Smith+Nephew (U.K.), Mölnlycke Health Care AB (Sweden), ConvaTec, Inc. (U.K.), Paul Hartmann AG (Germany), Organogenesis Inc. (U.S.), 3M (U.S.), Medtronic (Ireland), Covalon Technologies Limited (Canada), BSN Medical GmbH (Germany), Medline Industries, Inc. (U.S.), B. Braun Melsungen AG (Germany), Coloplast (Denmark), DermaRite Industries, LLC (U.S.), ETS Wound Care, LLC (U.S.), Hollister Incorporated (U.S.), Integra LifeSciences (U.S.), Johnson & Johnson Private Limited (U.S.) (China), Cardioline S.P.A. (Italy), SUZUKEN CO., LTD. (Japan)|
Key Segment Of The bioactive wound care market
By Product (USD Million)
• Moist Wound Care
• Active Wound Care
• Antimicrobial Wound Care
Wound Type (USD Million)
• Surgical Wounds
• Gunshot Wounds
• Traumatic Wounds
End user (USD Million)
• Trauma Centers
• Armed Forces
• Pharmacy Stores
Regional Overview (USD Million)
• Rest of Europe
• Rest of Asia Pacific
• Rest of South America
Middle East and South Africa